Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
TP53 signature diagnostic system using multiplex reverse transcription–polymerase chain reaction system enables prediction of prognosis of breast cancer patients
Ist Teil von
Breast cancer (Tokyo, Japan), 2021-11, Vol.28 (6), p.1225-1234
Ort / Verlag
Singapore: Springer Singapore
Erscheinungsjahr
2021
Link zum Volltext
Quelle
MEDLINE
Beschreibungen/Notizen
Background
TP53
status based on
TP53
signature, a gene expression profile to determine the presence or absence of
TP53
mutation, is an independent prognostic factor of breast cancer. The purpose of this study was to develop a simple diagnostic system for
TP53
signature status.
Methods
We developed a multiplex reverse transcription–polymerase chain reaction system to determine
TP53
status. Based on this system, prospectively collected 189 patients with stage I and II breast cancer were determined to have
TP53
mutant signature or
TP53
wild-type signature. The prognostic significance of the
TP53
signature by the diagnostic system was analyzed.
Results
The diagnostic accuracy of
TP53
status and reproducibility of this diagnosis system was confirmed. Using the diagnostic system, 89 patients were classified as
TP53
mutant signature and the remaining 100 cases were classified as
TP53
wild-type signature. Recurrence-free survival (RFS) among patients with
TP53
mutant signature was significantly shorter than that among those with
TP53
wild-type signature. On univariate and multivariate analyses, the
TP53
signature status was an independent predictor of RFS. RFS among patients with
TP53
mutant signature was significantly shorter than that among those with
TP53
wild-type signature in a cohort of estrogen receptor-positive breast cancer. Although a difference was not significant, no recurrent cases was observed in
TP53
wild-type signature group in triple negative breast cancer.
Conclusion
This simple and precise diagnostic system to determine
TP53
signature status may help in prognostic assessment, therapeutic decision-making, and treatment optimization in patients with breast cancer.